Pubblicazioni 2022
Bevacizumab-induced hypertension as a predictor of clinical outcome in metastatic colorectal cancer: An individual patient data-based pooled analysis of two randomized studies and a systematic review of the literature. Lombardi P, Rossini D, Crespi V, Germani MM, Bergamo F, Pietrantonio F, Santini D, Allegrini G, Daniel F, Pagani F, Antoniotti…
Pubblicazioni 2021
Prognostic and predictive impact of consensus molecular subtypes and CRCAssigner classifications in metastatic colorectal cancer: a translational analysis of the TRIBE2 study ESMO OPEN 2021 Mar 3;6(2):100073. doi: 10.1016/j.esmoop.2021.100073 Tumour mutational burden, microsatellite instability, and actionable alterations in metastatic colorectal cancer: Next-generation sequencing results of TRIBE2 study. Antoniotti C et…
Pubblicazioni 2020
Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial. Lancet Oncol. 2020 Mar 9. pii: S1470-2045(19)30862-9. doi: 10.1016/S1470-2045(19)30862-9. Phase III Randomized Study of Induction…
Pubblicazioni 2019
Impact of age and gender on the safety and efficacy of chemotherapy plus bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies. Ann Oncol. 2019 Dec;30(12):1969-1977. doi: 10.1093/annonc/mdz403. Epub 2020 Jan 8. Clinical and molecular determinants of extrahepatic disease progression in patients with metastatic colorectal cancer…
Pubblicazioni 2018
Prognostic and predictive role of neutrophil/lymphocytes ratio in metastatic colorectal cancer: a retrospective analysis of the TRIBE study by GONO Annals of Oncology 0: 1–7, 2018 doi:10.1093/annonc/mdy004 Published online 8 January 2018 Activity and Safety of Cetuximab Plus Modified FOLFOXIRI Followed by Maintenance With Cetuximab or Bevacizumab for RAS and…
Pubblicazioni 2017 – 2014
DPYD and UGT1A1 genotyping to predict adverse events during first-line FOLFIRI or FOLFOXIRI plus bevacizumab in metastatic colorectal cancer www.impactjournals.com/oncotarget/ Oncotarget, Advance Publications 2017 TRIBE-2: a phase III, randomized, openlabel, strategy trial in unresectable metastatic colorectal cancer patients by the GONO group BMC Cancer (2017) 17:408 DOI 10.1186/s12885-017-3360-z Serum LDH…
Pubblicazioni 2013 – 2004
FOLFOXIRI in combination with panitumumab as first-line treatment in quadruple wild-type (KRAS, NRAS, HRAS, BRAF) metastatic colorectal cancer patients: a phase II trial by the Gruppo Oncologico Nord Ovest (GONO). Ann Oncol. 2013 Aug;24(8):2062-7. doi: 10.1093/annonc/mdt165. Epub 2013 May 10. Outcome of second-line treatment after first-line chemotherapy with the GONO…